Francis Kynaston-Pearson: Why Randomised Controlled Trials Are the Gold Standard in Clinical Research
Francis Kynaston-Pearson, Consultant Rheumatologist at Mediclinic Middle East, shared a post on LinkedIn:
“The randomised control trial (RCT) – the ‘gold standard’ for clinical evidence.
If that is so, why is all evidence not gathered in such a manner.
For those in research, the answer is evident but doctors and scientists forget that the complexities of the nuts and bolts of a quality trial are not common knowledge of our patients.
Not all questions can be answered with an RCT, not to mention the cost in setting one up.
Trials with mild or moderate methodological failing or negative results may not even get published, with the hard work never known outside the investigating team.
For anyone who wanted a quick overview of RCTs but was a little afraid or embarrassed to ask, here is a quick video for you.”
Stay updated with Hemostasis Today.
-
Jun 18, 2026, 03:00Daniel Ben-Mordechay: Portal Vein Thrombosis – Recognizing a Potentially Life-Threatening Diagnosis with Ultrasound
-
Jun 18, 2026, 00:32Nibal Chamoun: Excited to Co-Moderate the Antithrombotic Stewardship Summit at ISTH 2026
-
Jun 17, 2026, 22:28Muntadhar Al Moosawi: A Tribute to the Compassion and Generosity of Cleveland Clinic Abu Dhabi’s Blood Donors
-
Jun 17, 2026, 20:06Hossam El Benawi: Who Can Safely Stop Anticoagulation after LVT Resolution?
-
Jun 17, 2026, 17:47Anuoluwapo Oladunjoye: Every Blood Film Has a Story to Tell
-
Jun 17, 2026, 17:46Svetislav Matic: A Patient-Centric Interdisciplinary Approach to Perioperative Bleeding Management
-
Jun 17, 2026, 17:45Paul Breillat: New Insights Into the Role of RIPK1-Mediated Cell Death in VEXAS syndrome
-
Jun 17, 2026, 17:44Konstantin Yenkoyan: New Publication Alert – Autism and Iron Dysregulation
-
Jun 17, 2026, 17:44Ifeanyichukwu Ifechidere: Why Fibrinolysis Matters as Much as Clot Formation